“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
+7
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. Were a clinical stage genome editing company focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Our goal is to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development...
Genome editing,in vivo (in body) editing,engineered cell medicines,ocular medicines,genetic diseases,blood diseases,sickle cell disease,cancer,rare diseases,immunogenetics,transfusion-dependent beta thalassemia,and hematopoietic stem cells
Editas medicine operates in the Biotechnology research industry.
Editas medicine's revenue is $32.31m
Editas medicine has 201 - 500 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.